Athersys to Participate in The American Society for Neural Therapy and Repair Annual Conference
22 April 2023 - 4:23AM
Business Wire
Athersys, Inc. (NASDAQ: ATHX), a regenerative medicine company
developing MultiStem® (invimestrocel) cell therapy for critical
care indications, announced today their participation in The
American Society for Neural Therapy and Repair Annual Conference
from April 27-30, 2023 in Clearwater, FL.
The American Society for Neural Therapy and Repair is a society
of basic and clinical neuroscientists with a mission to better
understand the way the nervous system functions and establish new
procedures for its repair in response to trauma or
neurodegenerative disease.
Dr. Sarah Busch, Vice President of Regenerative Medicine and
Head of Business Development, has been invited to participate in
this conference. On Friday, April 28th, she will be giving a talk
in the morning titled “MultiStem® Cellular Therapy for Neurological
Indications” during the Cell Therapies for Neural Repair session
and will participate in a panel discussion later in the day titled,
“Career Retention and Development of Female Neuroscientists.” On
April 29th, Dr. Busch will be co-chairing the “Translating
Treatments for Neural Injury & Disease” panel discussion.
“As a company with a broad pipeline focused on treatment of
neurological indications, we are excited for the opportunity to
share the progress we’ve made with MultiStem and engage with other
experts in the field of neuroscience,” commented Dr. Busch. “We are
enthusiastic about the potential for collaboration and knowledge
exchange that this event offers as we continue to drive forward in
our mission to extend and enhance the quality of human life."
The following are specific details regarding Dr. Busch's
participation in The American Society for Neural Therapy and Repair
Annual Conference:
Event:
Platform Presentation, “MultiStem®
Cellular Therapy for Neurological Indications”
Date:
Friday, April 28th, 2023
Time:
9:00 a.m. ET
Location:
Sheraton Sand Key Resort, Clearwater
Beach, Florida U.S.A.
Event:
Panel Discussion, “Career Retention and
Development of Female Neuroscientists”
Date:
Friday, April 28th, 2023
Time:
4:50 p.m. ET
Location:
Sheraton Sand Key Resort, Clearwater
Beach, Florida U.S.A.
Event:
Co-Chair for Panel Discussion,
“Translating Treatments for Neural Injury & Disease”
Date:
Saturday, April 29th, 2023
Time:
2:30 p.m. ET
Location:
Sheraton Sand Key Resort, Clearwater
Beach, Florida U.S.A.
Please visit https://www.asntr.org/ for additional information
and registration.
About Athersys
Athersys is a biotechnology company engaged in the discovery and
development of therapeutic product candidates designed to extend
and enhance the quality of human life. The Company is developing
its MultiStem® cell therapy product, a patented, adult-derived
“off-the-shelf” stem cell product, initially for disease
indications in the neurological, inflammatory and immune, and other
critical care indications and has several ongoing clinical trials
evaluating this potential regenerative medicine product. Athersys
has forged strategic partnerships and a broad network of
collaborations to further advance MultiStem cell therapy toward
commercialization. Investors and others should note that we may
post information about the Company on our website at
www.athersys.com and/or on our accounts on Twitter, Facebook,
LinkedIn or other social media platforms. It is possible that the
postings could include information deemed to be material
information. Therefore, we encourage investors, the media and
others interested in the Company to review the information we post
on our website at www.athersys.com and on our social media
accounts. Follow Athersys on Twitter at www.twitter.com/athersys.
Information that we may post about the Company on our website
and/or on our accounts on Twitter, Facebook, LinkedIn or other
social media platforms may contain forward-looking statements
within the meaning of the Private Securities Litigation Reform Act
of 1995 that involve risks and uncertainties. You should not place
undue reliance on forward-looking statements contained on our
website and/or on our accounts on Twitter, Facebook, LinkedIn or
other social media platforms, and we undertake no obligation to
publicly update forward-looking statements, whether as a result of
new information, future events or otherwise.
About MultiStem®
MultiStem® (invimestrocel) cell therapy is a patented
regenerative medicine product in clinical development that has
shown the ability to promote tissue repair and healing in a variety
of ways, such as through the production of therapeutic factors in
response to signals of inflammation and tissue damage. MultiStem
therapy’s potential for multidimensional therapeutic impact
distinguishes it from traditional biopharmaceutical therapies
focused on a single mechanism of benefit. The therapy represents a
unique "off-the-shelf" stem cell product that can be manufactured
in a scalable manner, may be stored for years in frozen form, and
is administered without tissue matching or the need for immune
suppression. Based upon its efficacy profile, its novel mechanisms
of action, and a favorable and consistent tolerability demonstrated
in clinical studies, we believe that MultiStem therapy could
provide a meaningful benefit to patients, including those suffering
from serious diseases and conditions with unmet medical need.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230421005284/en/
Athersys Ellen Gurley Manager of Corporate Communications
and Investor Relations ir@athersys.com
LHA Investor Relations Tirth T. Patel 212-201-6614
tpatel@lhai.com
Athersys (NASDAQ:ATHX)
Historical Stock Chart
From Apr 2024 to May 2024
Athersys (NASDAQ:ATHX)
Historical Stock Chart
From May 2023 to May 2024